Harvard Bioscience, Inc. (NASDAQ:HBIO) Position Boosted by Barclays PLC

Barclays PLC lifted its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 304.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 58,655 shares of the medical instruments supplier’s stock after purchasing an additional 44,150 shares during the quarter. Barclays PLC owned 0.13% of Harvard Bioscience worth $157,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in HBIO. State Street Corp increased its stake in Harvard Bioscience by 1.1% in the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock valued at $1,930,000 after buying an additional 7,763 shares during the period. Harvey Partners LLC grew its holdings in shares of Harvard Bioscience by 6.2% during the 3rd quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock valued at $7,303,000 after acquiring an additional 157,500 shares in the last quarter. Corsair Capital Management L.P. acquired a new position in shares of Harvard Bioscience in the third quarter worth $63,000. Advantage Alpha Capital Partners LP purchased a new stake in shares of Harvard Bioscience during the third quarter worth $64,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Harvard Bioscience during the third quarter worth $50,000. 80.87% of the stock is currently owned by institutional investors and hedge funds.

Harvard Bioscience Stock Performance

Shares of NASDAQ HBIO opened at $2.15 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91. Harvard Bioscience, Inc. has a one year low of $1.95 and a one year high of $4.99. The business’s 50-day moving average price is $2.23 and its two-hundred day moving average price is $2.61. The company has a market capitalization of $93.78 million, a P/E ratio of -6.51 and a beta of 1.27.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.